14.10.2022 13:35:21

Atara, Pierre Fabre Announce CHMP Adopts Positive Opinion Recommending Approval Of Ebvallo

(RTTNews) - Atara Biotherapeutics, Inc. (ATRA) and Pierre Fabre announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the European Commission approval of Ebvallo as a monotherapy for treatment of adult and pediatric patients two years of age and older with relapsed or refractory EBV+ PTLD, who have received at least one prior therapy. The CHMP positive opinion is based on results from the phase 3 ALLELE study.

The company said the EC's approval of the Ebvallo Marketing Authorization Application under exceptional circumstances is expected by the end of 2022.

Nachrichten zu Atara Biotherapeutics Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Atara Biotherapeutics Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!